The following information is disclosed in accordance with AIM Rule 26.
Last updated 1 September 18.

Business Description

Amryt is a commercial stage pharmaceutical company focused on acquiring, developing and commercialising innovative new treatments that help improve the lives of patients with rare and orphan diseases.

Our mission is to be a world leader in rare and orphan diseases.

Click here to find out more about us.

Incorporation & Registered Office

Country of Incorporation:
England & Wales

Main country of operation:

Company registration number:

Registered address:
Dept 920A
196 High Road
Wood Green
London N22 8HH

Company Directors

Harry Stratford (Non-Executive Chairman)
Joe Wiley (Chief Executive Officer)
Rory Nealon (Chief Financial Officer)
James Culverwell (Non-Executive Director)
Ray Stratford (Non-Executive Director)
Markus Zeiner (Non-Executive Director)

View directors’ biographies



Nominated Adviser
Shore Capital and Corporate Limited
Bond Street House
14 Clifford Street
London, W1S 4JU
United Kingdom
Joint Broker
Shore Capital Stockbrokers Limited
Bond Street House
14 Clifford Street
London, W1S 4JU
United Kingdom 
Joint Broker
Stifel Nicolaus Europe Limited
150 Cheapside
London, EC2V 6ET
United Kingdom 

ESM Adviser and Joint Broker
J & E Davy
Davy House
49 Dawson Street
Dublin 2
Grant Thornton
24-26 City Quay
Dublin 2

Link Asset Services
The Registry
34 Beckenham Road
Kent, BR3 4TU
United Kingdom 
Corporate Governance

The Quoted Companies Alliance (QCA) has published a corporate governance code for small and medium sized quoted companies, which includes a standard of minimum best practice for AIM companies and recommendations for reporting corporate governance matters (QCA Code). The QCA code is constructed around ten broad principles which the Company has chosen to apply to ensure good governance practices are in place.

Information on Corporate Governance can be found here.

UK Takeover code

The Company is subject to the UK City Code on Takeovers and Mergers.

Company Documents
Annual and Half Yearly Reports & Accounts

Annual and Half Yearly Reports & Accounts can be found here.

RNS Announcements

RNS announcements can be found here.

Details of Restrictions on the Transfer of Securities

There are no restrictions on the transfer of ordinary shares.

Details of any other Exchanges or Trading Platform

The shares of the Company are traded on the AIM market operated by the London Stock Exchange and the Enterprises Securities Market of the Irish Stock Exchange (Euronext Dublin).

Shares & Significant Shareholders

Total number of shares issued: 274,817,283

The identity and shareholdings of the Company’s significant shareholder can be found here.

Shares not in public hands

Pursuant to the AIM rules, and insofar as the Company is aware, as at 1 September 2018, 43.5% of the Company’s AIM Securities were not in public hands.

Page last updated: 21 September 2018